Registry for Hemoperfusion of Covid-19 ICU Patients

Completed

• Conditions: Multi Organ Failure; Systemic Inflammatory Response Syndrome; Viral Disease; Critical Illness; COVID-19 Acute Respiratory Distress Syndrome; AKI - Acute Kidney Injury
• Interventions: Device: Hemoperfusion

• Registration Number: NCT05470907
• Lead Sponsor: Croatian Society for Organ Support

Brief Summary

The ongoing COVID-19 pandemic caused high hospitalization and mortality rates especially in critically ill patients. Unfortunately, there is no present study with a large number of patients that would offer us clear answers on the treatment of ICU COVID-19 patients with adsorption filters, extracorporeal methods and the hemoperfusion method. The purpose of this registry study is to investigate the effectiveness and safety of the extracorporeal blood purification and hemoperfusion/hemadsorption filters in treating of critically ill COVID-19 patients.

Detailed Description

The COVID-19 pandemic has been associated with high mortality rate and high percentage of patients with with severe multi-organ dysfunction. Many therapies were investigated in this group of patients. The usage of extracorporeal blood purification, namely hemoperfusion/hemadsorption was introduced in everyday clinical practice even before COVID-19 pandemic in which became increasingly common. The efficacy of hemoperfusion/hemadsorption in removal of endotoxins and cytokines is still questioned by some physicians mostly due to the fact that some trials failed to demonstrate the effect of this therapy on long-term outcomes of critically ill patients. Unfortunately, there is no present study with a large number of patients that would offer us clear answers on the treatment of ICU COVID-19 patients with adsorption filters, extracorporeal methods and the hemoperfusion method. Several extracorporeal blood purification therapies have been proposed to attenuate systemic inflammation in COVID-19 patients but there is no study which analyzed more than one filter or patients without specific conditions. Due to these limitations the studies were not able to analyze the method itself. Therefore, the primary aim of this observational prospective, multi-centric, regional web-based registry is to define the results and outcome of treatment, possible advantages over patients who have not undergone targeted treatment and to set regional indications/inclusion criteria for the treatment of ICU COVID-19 patients with the method of hemoadsorption/hemoperfusion.

Study Timeline

• Study Start: 2022-07-21
• Study First Submitted: 2022-07-21
• Study First Submitted QC: 2022-07-21
• Study First Posted: 2022-07-22
• Status Verified: 2025-02
• Primary Completion: 2025-02-01
• Study Completion: 2025-02-05
• Last Update Submitted: 2025-02-11
• Last Update Posted: 2025-02-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1050

Inclusion Criteria

1. COVID-19 infection
2. laboratory and clinical evidence of systemic inflammation: high levels of inflammatory cytokines such as IL-6 (>25 pg / ml); high values of inflammatory parameters from serum (leukocytes >15x10 9 / l, CRP >40 mg / l, procalcitonin >0.9 mg / l) and a high SOFA score (>2).
3. diagnosed with sepsis or septic shock: sepsis is defined as the presence of suspected or documented infections along with systemic inflammatory response syndrome; septic shock is defined as the presence of sepsis and acute circulatory failure according to European criteria Society for Intensive Care Medicine
4. clinical symptoms of hemodynamic instability requiring vasopressors and initial signs immune dysregulation or cascade coagulation disorders
5. acute kidney injury assessed according to KDIGO / AKIN criteria: increase in serum creatinine ≥ 0.3 mg / dL within 48 hours, or ≥ 50% over 7 days, or hourly diuresis <0.5 mL / kg / h for more than 6 hours
6. diagnosis of ARDS
7. the need for ECMO
8. deterioration of respiratory status with the onset of respiratory failure requiring mechanical ventilation (respiration rate >30 / min, or oxygen saturation <93%, or PaO2 / FiO2 ratio <300mmHg).
9. Admission to ICU

Exclusion Criteria

• besides contraindications to the use of the hemoperfusion adopted (as from the manual of instructions), there are no exclusion criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
EBP	Hemoperfusion	ICU COVID-19 patients treated with hemoperfusion/hemadsorption

Primary Outcome Measures

Name	Time	Method
Define the inclusion criteria for hemoperfusion in ICU COVID-19 patients	28 days	Define the inclusion criteria for extracorporeal blood purification (hemoperfusion) with different filters/hemadsorbers in ICU COVID-19 patients

Secondary Outcome Measures

Name	Time	Method
To assess the correlation between hemoperfusion and positive short-term outcome	72 hours after finishing all the hemoperfusion procedures	Define as to assess the correlation between hemoperfusion and positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).
To assess the correlation between hemoperfusion and positive long-term outcome	28 days	To assess the correlation between hemoperfusion and positive long-term outcome, defined as patient survival at ICU discharge.
To assess the correlation between different filters/hemadsorbers and positive short-term outcome	72 hours after finishing all the hemoperfusion procedures	Define as to assess the correlation between different filters/hemadsorbers and positive long-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).
To assess the correlation between different filters/hemadsorbers and positive long-term outcome	28 days	To assess the correlation between different filters/hemadsorbers and positive long-term outcome, defined as patient survival at ICU discharge.
The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive long-term outcome	28 days	The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive long-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).
The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome	72 hours after finishing all the procedures with the combination of filters/hemadsorbers and extracorporeal organ support therapy	The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).

Trial Locations

Locations (1)

University Hospital Center Zagreb; 🇭🇷 Zagreb, Grad Zagreb, Croatia